Information Provided By: 
Fly News Breaks for March 31, 2016
AGIO
Mar 31, 2016 | 07:52 EDT
JPMorgan analyst Anupam Rama cut his price target for Agios Pharmaceuticals to $39 saying the company is "just not there yet" on its pyruvate kinase deficiency program. Early data from the phase 2 study of AG-348 in PKD and phase 1 AG-519 healthy volunteer data will be presented at European Hematology Association conference midyear, Rama tells investors in a research note. The analyst thinks the shares could be range-bound, and sees potential for downside risk, as he is not expecting a clear hemoglobin signal. He keeps a Neutral rating on Agio.
News For AGIO From the Last 2 Days
There are no results for your query AGIO
